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Exploring Data Quality Management within Clinical Trials 
Abstract 
Background Clinical trials are an important research method for improving medical knowledge and 
patient care. Multiple international and national guidelines stipulate the need for data quality and 
assurance. Many strategies and interventions are developed to reduce error in trials, including standard 
operating procedures, personnel training, data monitoring, and design of case report forms. However, 
guidelines are nonspecific in the nature and extent of necessary methods. 
Objective This article gathers information about current data quality tools and procedures used within 
Australian clinical trial sites, with the aim to develop standard data quality monitoring procedures to 
ensure data integrity. 
Methods Relevant information about data quality management methods and procedures, error levels, 
data monitoring, staff training, and development were collected. Staff members from 142 clinical trials 
listed on the National Health and Medical Research Council (NHMRC) clinical trials Web site were invited 
to complete a short self-reported semiquantitative anonymous online survey. 
Results Twenty (14%) clinical trials completed the survey. Results from the survey indicate that 
procedures to ensure data quality varies among clinical trial sites. Centralized monitoring (65%) was the 
most common procedure to ensure high-quality data. Ten (50%) trials reported having a data 
management plan in place and two sites utilized an error acceptance level to minimize discrepancy, set at 
<5% and 5 to 10%, respectively. The quantity of data variables checked (10–100%), the frequency of visits 
(once-a-month to annually), and types of variables (100%, critical data or critical and noncritical data 
audits) for data monitoring varied among respondents. The average time spent on staff training per 
person was 11.58 hours over a 12-month period and the type of training was diverse. 
Conclusion Clinical trial sites are implementing ad hoc methods pragmatically to ensure data quality. 
Findings highlight the necessity for further research into “standard practice” focusing on developing and 
implementing publicly available data quality monitoring procedures. 
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Background: Clinical trials are an important research method for improving medical 
knowledge and patient care. Multiple international and national guidelines stipulate the 
need for data quality and assurance. Many strategies and interventions are developed to 
reduce error in trials, including standard operating procedures, personnel training, data 
monitoring and design of case report forms. However, guidelines are non-specific in the 
nature and extent of necessary methods. Objective: To gather information about current 
data quality tools and procedures used within Australian clinical trial sites, with the aim 
to develop standard data quality monitoring procedures to ensure data integrity. 
Methods: Relevant information about data quality management methods and procedures, 
error levels, data monitoring, staff training, and development were collected. Staff 
members from 142 clinical trials listed on the National Health and Medical Research 
Council (NHMRC) clinical trials website were invited to complete a short self-reported 
semi-quantitative anonymous online survey. Results: Twenty (14%) clinical trials 
completed the survey. Results from the survey indicate that procedures to ensure data 
quality varies among clinical trial sites. Centralized monitoring (65%) was the most 
common procedure to ensure high-quality data. Ten (50%) trials reported having a data 
management plan in place and two sites utilized an error acceptance level to minimize 
discrepancy, set at <5% and 5-10%, respectively. The quantity of data variables checked 
(10-100%), the frequency of visits (once-a-month to annually), and types of variables 
(100%, critical data or critical and non-critical data audits) for data monitoring varied 
among respondents. The average time spent on staff training per person was 11.58 hours 
over a 12-month period and the type of training was diverse. Conclusion: Clinical trial 
sites are implementing ad-hoc methods pragmatically to ensure data quality. Findings 
highlight the necessity for further research into “standard practice” focusing on 
developing and implementing publically available data quality monitoring procedures.  
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1. Background and Significance  
Clinical trials are an important research method for improving medical knowledge 
and patient care. Evidence has linked poor data quality to incorrect conclusions and 
recommendations [1-4]; therefore, data quality is of paramount importance for acquiring 
reliable research findings from clinical trials [5, 6]. As poor data quality may stem from 
error; therefore, preventing data error is just as important as the development, design, and 
collection of clinical trial data [7]. Assessment of all possible sources of error, including 
data recording, abstraction, transcription, entry, coding and/or cleaning processes, 
contributes to improving data quality for clinical trials [8]. 
 
Many strategies and interventions have been developed aiming at reducing error in 
clinical trials, including standard operating procedures (SOPs), personnel training, data 
monitoring and design of case report forms (CRF). Additionally, multiple international 
and national guidelines stipulate the need for data quality and assurance, however, they 
are non-specific in the nature and extent of the necessary methods. These guidelines 
include the International Conference on Harmonisation  Good Clinical Practice 
(ICHGCP) guideline E6 (1996)[9] updated in 2015, guideline E6(R2)[10]; the 
International Standards Organisation (ISO) Clinical Investigation of Medical Devices for 
Human Subjects – GCP (2011) (ISO 14155:2011)[11]; the Food and Drug Administration 
(FDA) Guidelines for Monitoring of Clinical Investigations (1998) updated in 2013[12]; 
the European Union’s Clinical Trial Directive 2001/20/EC (2001)[13], updated in 2009 
and the Australian Government’s National Statement on Ethical Conduct in Human 
Research, (1999), updated, in 2007[14].  
 
 
According to ICHGCP, clinical trials must protect the rights and safety of all patients 
and ensure trial results are legible and valid. On-site monitoring is important to achieve 
high data quality and to ensure the method of source data verification1 (SDV) fulfils the 
original objectives [15].To optimize the efficacy of monitoring there has been an 
emphasis on data audits and reducing on-site monitoring [10, 11]. However, the ICHGCP 
guidelines are flexible in interpretation and do not provide specific details on how and 
when to conduct audits, or how much or how little monitoring is required to maintain 
data integrity [16, 17]. There is a lack of evidence to support intensive monitoring for 
data quality, in fact, updated guidelines promote alternative monitoring methods, such as 
risk-based approaches2, centralized3 and remote monitoring4, that complement trial 
procedures by improving the use of resources available [12, 18-20]. Although a reduction 
in on-site monitoring is suggested (updated ICHGCP guidelines re [21, 22]), the majority 
of clinical trials continue to conduct traditional 100% SDV[23]. Lack of clear guidance 
on which monitoring method is valid and cost-effective to ensure data integrity creates 
confusion within the clinical research community. A reduction in on-site SDV and the 
risk of missing critical issues are tradeoffs that more efficient, modern monitoring 
approaches need to consider. 
                                                 
1
 Source data verification (SDV) defines the process of comparing data collected on original source 
documents to data recorded on a case report form (CRF) either on paper or electronic records 
2
 Risk-based approach includes a mixed method approach focused on the critical data points an 
processes that are identified to have the most risk via a targeted or triggered assessment.  
3
 Centralized monitoring is a remote evaluation carried out by the sponsor personnel or representatives 
at a location other than the sites at which the clinical investigation is being carried out on a real time basis.  
4
 Remote monitoring is off-site monitoring of activities previously conducted on-site. Documents are 




Due to a growing concern about the effectiveness and efficiency of monitoring 
procedures, Brosteanu et al. (2017) conducted a clustered randomised study comparing 
intensive on-site monitoring and risk-adapted monitoring. Results found the benefit of 
intensive on-site SDV to be small (8.2%) when compared to risk-based monitoring, 
which utilized less than 50% of resources whilst ensuring the same level of GCP 
compliance [18]. It is evident that standardized approach needs to be adopted for 
monitoring of data quality in clinical research. In support of this notion, a survey 
conducted by the Clinical Trials Transformation Initiative (CTTI) investigated the 
intensity, focus, and methodology of monitoring practices by clinical research sponsors 
over a range of trial settings [24]. It was found that there is heterogeneity within and 
between organizational types including academic/government, clinical research 
organizations, and industry. 
Evidence of the effect of non-standardized data quality checks within clinical 
trials is the online blog of publication retractions due to fraudulent data [25]. This website 
lists 484 publications in 2017 alone that had to be withdrawn due to incorrect 
data/analysis. There appears to be a lack of knowledge about systematic methods and 
procedures for data quality assessment in clinical trials [1].To ensure data integrity in 
clinical research it is imperative to introduce a ‘gold standard methodology’ so that 
manuscripts can be published referencing their methods employed and the broader 







The objective of this feasibility study was to gather information about current data 
quality tools and procedures used within Australian clinical trial sites, with the aim to 
develop a standard data quality monitoring procedures to ensure data integrity. 
 
3. Methods 
3.1. Setting  
Clinical trial sites listed on the Australian Government National Health and 
Medical Research Council (NHMRC) Australian Clinical Trial site list were invited to 
participate in this survey (n=148) [5, 26]. Employees targeted to complete the survey 
included the manager/employee in charge of trial-related data quality assurance 
processes. The NHMRC clinical trial list was determined as a representative sample of 
Australian clinical trials including all phases (I-IV) and types (treatment, 
diagnostic/screening, and prevention) of clinical trials.  
Clinical trial sites that were identified to have an affiliation with the University of 
Wollongong (UoW), the organization that the researchers were employed, were excluded 
from the study to avoid the potential risk of bias. Any overlapped sites which, may cause 
duplication, were also excluded. Several clinical trial networks on the list responded that 
they did not run clinical trials independently. In this case, permission was given for these 
networks to forward the survey to their collaborating organizations that run clinical trials. 




3.2. Development of the online questionnaire survey form 
Eleven survey questions were adapted in short form from the published and 
validated survey questions [24, 27]. Information gathered from the survey included data 
quality management methods and procedures, error levels, data monitoring, staff training, 
and development (see Appendix A).  
Construct validation was completed by a convenience sample of ten UoW 
researchers who reviewed survey questions to ensure that the intended concept was 
assessed. Participants were also asked to comment on any procedural, usability and 
transparency issues faced in completing the survey. Expert advice from a data 
management manager was sought to ensure content validity, question clarity and answers 
fully address the research questions. The online questionnaire survey was designed using 
the Research Electronic Data Capture (REDCap) tool hosted at the University of 
Wollongong [28].  
3.3. Survey administration  
A cross-sectional study design was applied to get an overview of the current 
quality tools and practices implemented in Australian clinical trials. Invitations for 
participation were sent to the identified contact person for each clinical trial site via 
email. The email contained a brief introduction and a direct link to the survey. Each 
clinical trial site was provided with an individual identification code and three email 
reminders were sent over a four-month period to non-respondents. Clinical trial sites were 
asked to forward the survey to their collaborating sites using the same individual 
identification code if they were identified to be clinical institute network. 
 
 
3.4. Data analysis  
Questionnaire responses were standardized into categorical options and 
numerically coded for analysis. Statistical analyses were conducted using IMB SPSS 
software (Version 22, IMB Australia, Lane Cove, NSW, Australia). Data was explored 
via descriptive statistical analyses. Free text responses were analyzed using the six phases 
of thematic analysis [29] and conducted using NVivo qualitative data analysis Software  
(QRS International Pty Ltd. Version 10, 2012). Ethics approval was obtained from the 
University of Wollongong Human Research Ethics Committee (HE16/131).  
 
4. Results 
Of the 148 clinical trial sites identified, 142 initial invitations were sent out, see 
Figure 1. A total of 34 clinical trial sites consented to participate in the online survey, 
yielding a response rate of 24%. Of the 34 responses, 14 were excluded from the analyses 
due to missing data for >25% of survey questions. Three clinical networks asked to 
forward the survey invitation email to respondents that were more appropriate as well as 
to their collaborating sites. Finally, 20 clinical trial sites completed the survey in full and 
were included in data analysis. Table 1 listed the number and types of clinical trial sites. 
At each site, more than one type of clinical trial was conducted at any point in time.  
4.1. Data management and monitoring  
At the time of the survey, ten sites (50%) reported having a clinical data 
management plan in place and the majority (n=19) had implemented at least one or more 
procedures to ensure data quality (see Table 2). Only two sites set an error acceptance 
 
 
level, <5% and 5-10%, respectively, both responding that no follow-up or further 
monitoring was conducted if the error rate was found to be higher than the error 
acceptance level.  
The structure of data monitoring was reported in terms of variables to be selected, 
its coverage and amount, and time of execution. Monitoring 100% of the data points was 
the most common (n=7) response, although the procedures implemented varied greatly, 
and the amount of data included in monitoring ranging from 10-100%. The timing of data 
monitoring varied and was specific to the clinical trial and study design. The frequency of 
data monitoring varied among the six sites (30%) from monthly to annually. The 
variables included in data monitoring were completed on all (100%) data points (n=5), 
only critical data points (n=1), critical and non-critical data points defined by each study 
(n=3) or were dependent on the clinical trial (n=3). When asked about how their data was 
monitored, seven sites (35%) reported that they implemented at least one or more 
sampling techniques to extract data points, seven sites (35%) did not know and one site 
(5%) did not implement sampling techniques at all, see table 2 for further details.   
4.2. Training and development 
A certain type of staff training and development devoted to data quality were 
conducted at all clinical trial sites (100%, see Table 3). The average amount of time spent 
on staff training and development per person, per clinical trial was 11.58 ± 9.01 hours, 
(range 2 to 30) over a 12-month period.  
The personnel responsible for reviewing the reports of data quality and 
consistency varied from chief investigators (65%), auditor/monitor (60%), the data 
 
 
manager (55%) and sponsor (50%). In total, 75% of respondents answered that more than 
one person reviewed the reports.  
 
 
5. Discussion  
This feasibility study highlights the heterogeneity of data quality management 
practices within Australian clinical trials. Only 50% of the respondent clinical trial sites 
currently had a clinical data management plan in place, confirming our proposition that 
developing and maintaining a data management system is a challenge for clinical trials 
[30]. This is also in accordance with a recently published survey (26). This survey 
reported considerable variation in data management, with over 50% of clinical research 
centres having a data management system but many did not comply with guidelines and 
legal requirements (GCP and FDA)[27]. There are many reasons for this, such as 
individual clinical trials implementing different procedures dictated by the sponsor, or 
monetary constraints in academic versus pharmaceutical clinical trials [31].  
Centralised and remote monitoring were found to be the most common data 
monitoring methods utilized although there appeared to be a lack of credible literature to 
suggest the advantage of these ‘newer’ methods over the more traditional approaches 
[20]. This study identified that 50% of sites still use traditional data monitoring methods 
such as 100% on-site SDV, which is an expensive, labor-intensive activity [32] and does 
not guarantee error-free results [33]. Andersen et al. [34] compared the effect of partial 
SDV and traditional 100% SDV using post hoc analyses of three-phase III randomised 
control trials. Because completing traditional 100% SDV monitoring only reduced error 
 
 
marginally (0.26%) compared to partial SDV, the authors challenged the belief that a 0% 
error rate is not an achievable goal. Only 2 out of 20 trial sites in our survey reported 
having a set error acceptance level, being ≤10%, which is in line with published literature 
[8, 35, 36]. One of the two clinical trial sites stated that they implemented a 5-10% 
threshold range, however, no further comment on why or when a different threshold for 
data validation was adhered to. As the survey was administered to clinical trial sites, the 
researchers have assumed that it might be possible that different clinical trial types have a 
tighter threshold than others; for example, a 5% threshold for a phase IV trials compared 
to 10% for epidemiological trials. Future research is required to explore the rationale for 
different levels of error acceptance within clinical trials.  
The major quality assurance activity reported to ‘prevent’ data errors was regular 
education and training of data collectors throughout the clinical trial. Although the 
majority of survey respondents reported that staff training and development was 
undertaken, the amount of training time varied greatly. Many researchers receive little to 
no training in regards to best practice for attaining, evaluating and controlling the quality 
of data collected. This is in line with the literature that reported due to the limitation of 
time and resources, not all research trials implement all the necessary data quality 
management tools and procedures [37].  
Within the pharmaceutical/private industries [38] and information sciences 
literature, data quality tools and procedures are well developed in which many 
frameworks acknowledge the multiple dimensions of data quality [39-44]. However, only 
a small body of clinical and health researchers have described the use of data quality 
frameworks [38, 45-48], and fewer have identified appropriate methods to quantify the 
 
 
quality of data [8]. Although many data quality dimensions and attributes have been 
determined within the clinical and health literature, the majority provides no usable 
definitions. Public sharing of this knowledge is crucial in developing a standardized 
approach that can be implemented across the clinical and broader research community to 
improve the rigor of clinical trials.    
5.1 Study limitations 
The results of this feasibility study are limited to clinical trials listed on the 
Australian NHMRC clinical trial site list. The survey results are subject to potential bias 
in a positive direction as the employee who completed the survey may be more 
knowledgeable about their organization’s data quality management procedures than those 
who chose to not participate. As clinical trial sites were recruited as an organization it is 
impossible for us to track if the person who completed the survey was best positioned to 
do so in the organization. In addition, the tools and procedures differed among clinical 
trials, which were influenced by overarching site policies. All these cause difficulty in 
interpreting results. The reason for low response rate might be clinical data audits and 
data management procedures are usually considered highly confidential by many research 
organizations and kept in-house [49].  As it is impossible to collect data about how many 
forwarding e-mails were sent by the clinical trial sites listed on the NHMRC website, this 
data was not accounted for in calculating a response rate. The low response rate means 
that the results of this survey should be used with caution. They may not be generalizable 
as a representative sample of clinical trial sites. Future research should include qualitative 
analysis through key-informant interviews with the provision of SOPs. This feasibility 
study was not designed to assess which data management tool is more effective, but 
 
 
rather to gather information about current data quality tools and procedures used within 
Australian clinical trials. Further research is required to fully examine the best method of 
monitoring data quality to assure and control data integrity in clinical research.research. 
At the conclusion of three studies, OPTI-misation of MONitoring (OPTIMON) 
[50], Strategic Timing of AntiRetrovial Treatment (START) trial Monitoring Substudy 
[51] and TargetEd Monitoring: Prospective Evaluation and refinement (TEMPER) study 
[52] the scientific community will have a better understanding of effective monitoring 
strategies.  At the conclusion of all three studies, empirical evidence will be provided and 
aid in improving the currently limited published procedures, as all three studies have 
different aims and designs in developing audit methodology.  
This research is part of a collaborative project and an important opportunity for 
clinical trial sites to bring together their existing experience to improve data quality 
management systems. It is recommended to further compare what is described in the 
literature and what is currently happening at a site level to identify the gaps, the 
facilitators and the barriers to implementing data quality management systems. To 
achieve the objective of informing the data quality improvement initiative over a broad 
spectrum of clinical trials, this critical information needs to be made freely available in 
the published literature.  
 
6. Conclusions 
This is the first survey gathering information about current data quality tools and 
procedures within Australian clinical trial sites. This survey found that clinical trial sites 
 
 
were implementing newer approaches such as centralized and remote monitoring despite 
the majority were still completing 100% SDV, a labor-intensive and cost-inefficient 
method. It is clear that data quality management procedures vary greatly between clinical 
trials sites, with only 50% of the trial sites with a data management plan in place. Further 
research is required to assess differences between data management tools and procedures 
between clinical trials within a clinical trial site. This will allow researchers to investigate 
what is “standard practice” and focus on developing and implementing publically 
available data quality monitoring procedures to ensure data integrity.  Data quality is 
essential for the reliability of scientific findings generated from the investment in clinical 
trials, adequate infrastructure, staff skills, management support and resources need to be 
in place to ensure data is effectively managed. It is time that quality assurance and quality 
control tools and procedures implemented in clinical trials are cited in all publications.  
  
 
Clinical Relevance Statement  
It is vital to ensure the scientific rigor of clinical trials to evaluate data quality 
management procedures and to assure the accuracy of findings and to reduce error. This 
survey highlights the heterogeneity of clinical trial’s data quality management practices 
in Australia. It thus suggests that ‘best practices’ need to be made freely available in the 
published literature. Adequate infrastructure, staff skills, management support and 
resources need to be considered and implemented to ensure high quality data and research 




Multiple Choice Question 
Question  
1. Which of the following data monitoring methods is the traditional approach that 
fulfills the International Conference on Harmonisation Good Clinical Practice 
(ICH-GCP) E6 guideline (1996)?  
a. Remote monitoring  
b. Source data verification 
c. Central monitoring 
d. Risk-based approach  
 
Answer – B: Source data verification 
Explanation: In 1996, the International Conference on Harmonisation (ICH) guideline E6 
on Good Clinical Practice (GCP) reported there is a need for on-site monitoring before, 
during and after a clinical trial. The practice of source data verification (SDV) fulfils the 
ICH-GCP requirements and is a process of comparing data collected on original source 
documents to data recorded on a case report form (CRF) or electronic record. Source 
documents are considered the “gold standard” from which data is obtained in clinical 
trials. Therefore, SDV is considered the traditional approach to monitoring data utilized 
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Appendix A: Online survey questions 
1. Does your institute currently have a clinical data management plan in place? 
2. What type of clinical research does your institute conduct?  
3. Does your institute have any of the following procedures in place to ensure high-
quality data is produced? 
4. What percentage of your data is monitored? 
5. Does your institute have an error acceptance level? 
6. Following on from Question 5, if the error rate is found to be higher than the 
approved acceptance level, does your institute implement further follow-up 
monitoring? 
7. How often does your institute conduct internal data monitoring? 
8. What variables are included in data monitoring? 
9. Does your institute use any of the following sampling techniques to select what 
data points are monitored? 
10. Please specify the type of staff training/development you conduct that is devoted 
to data quality for clinical trials.  




Table 1: Demographic characteristics of clinical trial site employees  
 
 
                                                 
1
 One clinical trial employee did not enter the current job title. 
Variable n(%) 
Gender  
     Male 0(0) 
     Female 20(100) 
Highest level of education  
     College/TAFE course 1(5) 
     Bachelor degree 12(60) 
     Doctoral degree 7 (35) 
Duration of current employment (years)   
     0 – 4  9(45) 
     5 – 9  7(35) 
     10 – 15  3(15) 
     + 15 1(5) 
Appointment (current job or position)  
     Continuing employment (no specified end date) 9(45) 
     Fixed-term contract (specified time or ascertainable period) (years) 11(55) 
          < 1         
          2 




Current job title (n=19)
1
  
     Research Fellow 
     Research Governance Officer 
     Manager 
     Clinical Trial/Study Coordinator 
     Chief Operating Officer 







Table 2: Type of clinical trial conducted at each site 
 
 




Phase II 14 
Phase III 14 
Quality of life 12 
Prevention 11 
Epidemiology 11 
Phase 1  10 
Phase IV 10 
Screening 9 
Diagnosis 7 
Genetic screening 6 












Currently have a clinical data management plan 10(50) 7(35) 3(15) - 
Procedures to ensure high-quality data 19(95) - 1(5) - 
 Centralized monitoring 13(65)    
 Remote monitoring 11(55)    
 Logic, range and consistency checks 11(55)    
 On-site source data verification 10(50)    
 Statistical techniques 7(35)    
 Risk-based targeted monitoring 5(25)    
 Risk-based triggered monitoring 3(15)    
Currently have an error acceptance level 2(10) 11(55) 7(35) - 
Percent of data monitored 14(70) - 5(25) 1(5) 
 10% 2(10)    
 20% 2(10)    
 75% 2(10)    
 100% 7(35)    
 
Amount of data monitored depends on data point/outcome 
measured 
1(5)    
Frequency of internal data monitoring 13(65) - 3(15) 5(25) 
 Every month 2(10)    
 Every 9 months 1(5)    
 Annually 3(15)    
 
Monitoring completed when data points are identified with 
issues of poor quality 
1(5)    
 Varies between projects and study design 5(25)    
Variables included in data monitoring 12(60) - 4(20) 4(20) 
 Critical data points 1(5)    
 Critical and non-critical data points 3(15)    
 All (100%) data points 5(25)    
 Varies between projects and study design 3(15)    
Sampling techniques to select data points
1
  7(35) 1(5) 5(25) 7(35) 
 Simple random sampling 4(20)    
 Systematic sampling 2(10)    
 Stratified sampling  2(10)    
 Cluster sampling 1(5)    
 Varies between projects and study design 1(5)    
Centralized monitoring: Data collected through an electronic data capture and queries identified by monitor that may need 
further attention to alleviate problems 
Remote monitoring: Data monitored off-site, includes delivering documents via email, fax or snail mail to monitors to 
conduct source data verification. 
Logic, range, and consistency check: Logic check, flag indicator results that fail a common-sense comparison to other 
indicator or other disaggregation; Range check, check the value of data to see if it is within a certain range; Consistency 
check, performed to determine if the data has an internal conflict and data field correspond 
On-site SDV: At the site comparing source data (original or certified copy) document to data recorded or entered to a case 
report form or electronic record or database. 
Statistic technique: For example cluster and outlier analysis. 
Risk-based targeted monitoring: Focus on a certain data point that has been identified to have the most risk. 
Risk-based triggered monitoring: After a certain event like a large number of adverse events or deviations further detailed 
monitoring occurs.  
 
                                                 
1
 Sampling technique refers to the way data points are selected to be a sample for data monitoring. 
Table 4: Type of staff training and development devoted to data quality 
Type of training/development n(%) 
Education throughout clinical trial (as needed) 13(65) 
ICH-GCP training 12(60) 
Group education and training 11(55) 
SOP training 11(55) 
Education prior to research 10(50) 
Skills training and development 7(35) 
One-on-one education and training 6(30) 
Not applicable 1(5) 
Other 1(5) 
ICH-GCP: International Conference on Harmonisation and Good Clinical Practice 
SOP: Standard Operating Procedure 
 
